We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

BioTek’s Gen5 Software Offers CVB Relative Potency Solution

Product News  
Published: August 14, 2014 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

By submitting your email address, you agree to receive email communications related to Technology Networks content, products, or our partners. You may unsubscribe from these communications at any time as we respect your privacy. View our Privacy Policy for more information.
Read time: Less than a minute

BioTek has announced the availability of customizable pre-programmed protocols for Gen5™ Data Analysis Software designed to estimate Relative Potency according to the requirements of the USDA APHIS Center for Veterinary Biologics (CVB) guidelines published March 14, 2014.

The CVBSOP0101.01 establishes the criteria that veterinary vaccine producers must use to estimate the relative potency of their test serials prior to submission for licensing through the CVB.

Several pre-programmed Gen5 protocols addressing both the full dose response and the linear methods for calculation are available for free download from BioTek’s website.

BioTek’s Gen5 capability provides CVB compliant laboratories with a convenient option to meet the stringent requirements of this SOP.

BioTek will be hosting a webinar on September 25, 2014 where they will describe the use of Gen5 software to estimate relative potency values per the CVB requirements.

Related Topic Pages
The Immune System
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter